News > AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials

AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials

AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalised with respiratory symptoms of Covid-19.

The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.